Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DANHEART: Hydralazine-ISDN and Metformin in Chronic Heart Failure
NCT03514108Phase 4Completed
- Start
- Mar 2018
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of isosorbide dinitrate + hydralazine and liquid metformin (Aspargo Labs) in heart failure (HF) (4 arms). Primary endpoints: H-HeFT combined primary endpoint at 4 years and Met-HeFT combined primary endpoint at 4 years. Started Mar 2018; status: completed.
02
Drugs
isosorbide dinitrate + hydralazineliquid metformin (Aspargo Labs)
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT03514108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03514108.